Another interesting molecular modulation of estrogen receptors, such as the nuclear ones, has been advanced by Wnuk et al. They aimed to explore the therapeutic potential of PaPE-1, a newly designed compound to selectively activate non-nuclear estrogen receptors, in the context of AD. This evidence concerns the gene ESR1 and Alzheimer disease.